Nav: Home

SphingoTec's kidney function biomarker penKid® accurately detects acute kidney injury in infants

August 27, 2020

Hennigsdorf/Berlin, Germany, August 27, 2020 - Diagnostics company SphingoTec GmbH ("SphingoTec") announced today the publication of first data (1), proving that its real-time kidney function biomarker penKid® is a reliable biomarker for the diagnosis of acute kidney injury (AKI) in infants. With the incidence of pediatric AKI increasing globally, there is a high need for non-invasive, diagnostic solutions to improve the early diagnosis of AKI in children to prevent adverse events and improve recovery.

penKid® is an established biomarker for detecting AKI in adults. The current study shows that reference values for penKid® in children are much higher than in adults. However, when considering these higher reference values in critically ill children under one year of age, high or increasing penKid® concentrations accurately predict AKI and its severity.

Dr. Andreas Bergmann, CEO of SphingoTec, commented: "The data confirm, that penKid® predicts AKI also in challenging settings such as the pediatric critical care. In critically ill children, AKI has a high prelevance, is associated with poor outcomes and the possibilities for pharmacological intervention are limited. Therefore, the early detection of AKI is paramount in improving the prognosis for these children."

In children admitted to hospital, AKI is a common complication especially among those requiring intensive care, affecting up to 51% admitted to ICU (2). Pediatric AKI is often diagnosed too late for successful therapeutic interventions leading to adverse outcomes and chronic kidney impairment. The data from the recent study highlight that penKid® has the potential to address this diagnostic shortcoming. The study data add to the rapidly growing body of evidence in by now more than 30,000 adult patients, showing that penKid® is an early and accurate indicator for the worsening or improvement of kidney function. Importantly, penKid® is independent of inflammation and comorbidities and, as recently published, the most accurate surrogate marker for true glomerular filtration rate (true GFR) in patients with renal impairment (3) and hence ideally suited for the real-time assessment of kidney function and the early prediction of AKI.
-end-
References (1) Hartman et al (2020), Proenkephalin as a New Biomarker for Pediatric Acute Kidney Injury - Reference Values and Performance in Children Under One Year of Age, Clin Chem Lab Med, doi: 10.1515/cclm-2020-0381. (2) Sutherland et al (2015) AKI in Hospitalized Children: Comparing the pRIFLE, AKIN, and KDIGO Definitions, Clin J Am Soc Nephrol, doi: 10.2215/CJN.01900214. (3) Beunders, R. et al.(2020), Proenkephalin compared to conventional methods to assess kidney function in critically ill sepsis patients, Shock, doi:10.1097/SHK.0000000000001510

About sphingotec

SphingoTec GmbH ("SphingoTec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin (bio-ADM®), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid®), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression. IVD tests for SphingoTec's proprietary biomarkers are made available as sphingotest® microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.

About penKid®

sphingotest® penKid® measures proenkephalin (penKid®), a stable fragment of the kidney stimulating hormone enkephalin. penKid® has been demonstrated to be a real-time surrogate biomarker for glomerular filtration rate, the gold standard to assess renal function. Measuring penKid® blood concentrations allows for timely information on kidney function in critically ill patients. Early assessment of worsening and improving of renal function on intensive care units and in emergency departments allows adjustment of nephrotoxic drug administration and the initiation of kidney-protective strategies to prevent acute kidney injury and thereby improve outcomes.

sphingotec GmbH

Related Kidney Function Articles:

Cancer drug can rebalance kidney function in a devastating genetic disease
Researchers at the University of Cambridge and the University of Zurich have discovered that a drug newly approved for cancer improves kidney dysfunction in a mouse model of Dent disease 2 and Lowe syndrome
SphingoTec's kidney function biomarker penKid® accurately detects acute kidney injury in infants
penKid® (Proenkephalin), a unique biomarker for the real-time assessment of kidney function.
Use of cystatin C for precise assessment of kidney function and cardiovascular risk
In many situations, it is essential that the physician knows a patient's kidney function as precisely as possible.
Young sugarcane workers at high risk of kidney function decline
Researchers from the Center for Health, Work and Environment (CHWE) at the Colorado School of Public Health have published a paper in PLoS-ONE, studying the decline in kidney function for young, first-time sugarcane workers in Guatemala.
Protein levels in urine after acute kidney injury predict future loss of kidney function
High levels of protein in a patient's urine shortly after an episode of acute kidney injury is associated with increased risk of kidney disease progression, providing a valuable tool in predicting those at highest risk for future loss of kidney function.
Kidney function may affect risks associated with prescription opioids
Compared with other pain medications, prescription opioids were linked with higher risks of death and hospitalization, particularly with higher doses.
Comparing major adverse cardiovascular events among patients with diabetes, reduced kidney function treated with metformin or sulfonylurea
This observational study compared major cardiovascular events (including hospitalization for heart attack, stroke, transient ischemic attack or cardiovascular death) among patients with diabetes and reduced kidney function treated with metformin or a sulfonylurea (a class of drugs to treat diabetes).
Fluoride may diminish kidney and liver function in adolescents, study suggests
luoride exposure may lead to a reduction in kidney and liver function among adolescents, according to a study published by Mount Sinai researchers in Environment International in August.
Higher kidney function at dialysis start linked with greater risk of death in children
In an analysis of information on children with kidney failure who began dialysis in the United States between 1995 and 2015, the risk of death was 1.36 times higher among children with higher kidney function at dialysis initiation.
Indigestion remedy slows kidney function decline and improves survival in late-stage CKD
As chronic kidney disease (CKD) progresses, the kidneys become less able to maintain a healthy balance of acids in the body.
More Kidney Function News and Kidney Function Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.